SAZ has been the topic of several other research reports. S&P Global set a €74.40 ($91.85) target price on shares of STADA Arzneimittel and gave the company a sell rating in a research report on Friday, November 10th. Nord/LB set a €74.40 ($91.85) price target on shares of STADA Arzneimittel and gave the stock a sell rating in a research note on Wednesday, November 29th. Commerzbank set a €66.25 ($81.79) price target on shares of STADA Arzneimittel and gave the stock a sell rating in a research note on Tuesday, December 26th. Finally, Independent Research set a €82.00 ($101.23) price target on shares of STADA Arzneimittel and gave the stock a neutral rating in a research note on Friday, November 10th. Five equities research analysts have rated the stock with a sell rating and two have assigned a hold rating to the stock. The company presently has an average rating of Sell and a consensus price target of €73.49 ($90.73).
Shares of STADA Arzneimittel (ETR SAZ) opened at €86.22 ($106.44) on Friday. STADA Arzneimittel has a 52-week low of €53.41 ($65.94) and a 52-week high of €90.24 ($111.41). The stock has a market cap of $5,370.00 and a PE ratio of 62.93.
COPYRIGHT VIOLATION NOTICE: This report was originally reported by Ticker Report and is the property of of Ticker Report. If you are viewing this report on another publication, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this report can be viewed at https://www.tickerreport.com/banking-finance/3258353/warburg-research-analysts-give-stada-arzneimittel-saz-a-74-40-price-target.html.
STADA Arzneimittel Aktiengesellschaft engages in the development and marketing of active pharmaceutical ingredients for the health care and pharmaceutical markets worldwide. It operates through two segments, Generics and Branded Products. The Generics segment provides various generic active ingredients, including Tilidine naloxone for pain; Atorvastatin for elevated cholesterol levels; Pantoprazole for stomach ulcer/reflux; Diclofenac for pain/inflammation; and Enalapril for high blood pressure indications.
Receive News & Ratings for STADA Arzneimittel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STADA Arzneimittel and related companies with MarketBeat.com's FREE daily email newsletter.